{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:17:29Z","timestamp":1791400649117,"version":"4.3.3"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bestpracticeobgyn.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.bpobgyn.2016.11.004","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T06:37:12Z","timestamp":1479883032000},"page":"126-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4350-0884","authenticated-orcid":false,"given":"Kate","family":"Webber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2016.11.004_bib1","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.1996.14.11.2968","article-title":"Natural history and prognosis of untreated stage I epithelial ovarian carcinoma","volume":"14","author":"Ahmed","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian Cancer","volume":"322","author":"Young","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib3","series-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","author":"Lawrie","year":"2015"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","article-title":"Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer\u2013Adjuvant ChemoTherapy in Ovarian Neoplasm trial","volume":"95","author":"Trimbos","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib5","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/djq149","article-title":"Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial","volume":"102","author":"Trimbos","year":"2010","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ejca.2009.12.012","article-title":"Understanding the problem of inadequately staging early ovarian cancer","volume":"46","author":"Timmers","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"The Lancet"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.1992.10.5.706","article-title":"Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer","volume":"10","author":"Alberts","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib10","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib11","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel\u2013carboplatin versus paclitaxel\u2013carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2009.10.073","article-title":"The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study","volume":"116","author":"Chan","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib14","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.bjc.6603116","article-title":"Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging","volume":"94","author":"Takano","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib15","series-title":"NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer","author":"National Comprehensive Cancer Network","year":"2016"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib16","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1200\/JCO.2011.40.1646","article-title":"Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation","volume":"30","author":"Hoskins","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib17","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jnci\/djj443","article-title":"Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments","volume":"98","author":"Kyrgiou","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib18","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"du Bois","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/jnci\/djq362","article-title":"Advanced ovarian cancer: phase III randomized study of sequential cisplatin\u2013topotecan and carboplatin\u2013paclitaxel vs carboplatin\u2013paclitaxel","volume":"102","author":"Hoskins","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib22","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.ejca.2010.06.124","article-title":"Paclitaxel\/carboplatin versus topotecan\/paclitaxel\/carboplatin in patients with FIGO suboptimally resected stage III\u2013IV epithelial ovarian cancer a multicenter, randomized study","volume":"46","author":"Bolis","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib23","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.ejca.2008.06.035","article-title":"Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: A Hellenic Cooperative Oncology Group (HeCOG) study","volume":"44","author":"Aravantinos","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib24","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1200\/JCO.2006.09.7527","article-title":"Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-Line treatment of advanced ovarian cancer: Intergroup Trial of the AGO-Ovar\/AIO and EBMT","volume":"25","author":"M\u00f6bus","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib25","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib26","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bpobgyn.2016.11.004_bib28","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib29","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib32","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.tps5611","volume":"32","author":"Hook","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: A Gynecologic Oncology Group Study","volume":"33","author":"Tewari","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib35","series-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2016"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1525-1438.2006.00846.x","article-title":"A\u00a0meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer","volume":"17","author":"Hess","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","article-title":"Health-related quality of life During and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group Study","volume":"25","author":"Wenzel","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0090-8258(91)90266-8","article-title":"Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system","volume":"41","author":"Davidson","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib40","doi-asserted-by":"crossref","unstructured":"Walker J, Brady MF, DiSilvestro PA, et\u00a0al. A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study. 2016 Soc Gynecol Oncol Annu Meet n.d.; Late-breaking abstract 6.","DOI":"10.1016\/j.ygyno.2016.04.535"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"The Lancet"},{"issue":"32","key":"10.1016\/j.bpobgyn.2016.11.004_bib43","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1200\/JCO.2016.68.1239","article-title":"Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer","volume":"34","author":"Meyer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.bpobgyn.2016.11.004_bib44","first-page":"1254","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"12","author":"Wright","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1006\/gyno.1996.0065","article-title":"Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease","volume":"60","author":"Goff","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib46","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib47","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","article-title":"Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial","volume":"34","author":"Sugiyama","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib48","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/IGC.0000000000000677","article-title":"Molecular profiling of clear cell ovarian cancers","volume":"26","author":"Friedlander","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib49","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5528","article-title":"Multicentre trial of carboplatin\/paclitaxel versus oxaliplatin\/capecitabine, each with\/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC)","volume":"33","author":"Gore","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib51","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","article-title":"Gynecologic cancer intergroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas","volume":"24","author":"Gourley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib52","series-title":"Maintenance chemotherapy for ovarian cancer","author":"Mei","year":"2013"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib53","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib54","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical Trials in Recurrent Ovarian Cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib55","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: What is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib56","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib57","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","year":"2003","journal-title":"The Lancet"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib58","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib59","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib60","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/207084","article-title":"Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review","volume":"2010","author":"Makrilia","year":"2010","journal-title":"Met-Based Drugs"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2004.08.002","article-title":"Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell\/IgE-mediated reactions","volume":"95","author":"Lee","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0090-8258(03)00066-0","article-title":"Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation","volume":"89","author":"Jones","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib64","doi-asserted-by":"crossref","first-page":"199.e1","DOI":"10.1016\/j.ajog.2007.04.044","article-title":"Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer","volume":"197","author":"Callahan","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib65","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib67","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib68","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib69","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib70","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.2008.18.9548","article-title":"Phase II evaluation of nanoparticle albumin\u2013bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer","volume":"27","author":"Teneriello","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib71","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1200\/JCO.2005.09.032","article-title":"Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails","volume":"23","author":"Sessa","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib72","series-title":"Topotecan for ovarian cancer","author":"Lihua","year":"2008"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib73","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/bjc.1995.453","article-title":"Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience","volume":"72","author":"Gore","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib74","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S0002-9378(12)91832-3","article-title":"Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial","volume":"170","author":"Seewaldt","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib75","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib76","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib77","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2008.19.2963","article-title":"Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A Study of the Gynecologic Oncology Group","volume":"27","author":"Miller","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib78","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ejca.2008.12.013","article-title":"A\u00a0randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer","volume":"45","author":"Vergote","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib79","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.11.004_bib80","article-title":"Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant\/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS)","volume":"34","author":"Roncolato","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693416301390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693416301390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T18:08:50Z","timestamp":1568570930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693416301390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":80,"alternative-id":["S1521693416301390"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.11.004","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}